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the 6 new oncology drugs reimbursed by AIFA in 2014 with average times from the 
national reimbursement decision to the regional one ranging from 3 months in 
Piemonte to 5 months in Emilia Romagna. The Lazio and Sardinia Regions have 
evaluated only 1 out of the 6 drugs with an access time of around 2.5 and 6 months, 
respectively. ConClusions: In Italy, the average times from the national reim-
bursement decisions to the regional evaluations aiming to the formulary inclusion 
vary widely between Regions.
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objeCtives: To undertake a pragmatic, comparative analysis of cancer care path-
ways to identify drivers of improving cancer survival across Europe, using colon 
cancer as a case study. Methods: We conducted a review of data from interna-
tional, European and UK cancer databases and registries, focusing on the identi-
fication of variations in overall and colon cancer care and survival. Additionally, 
we investigated variation in national access to, as well as utilisation and speed 
of adoption of, biologic cancer treatments, a recognised source of improving can-
cer outcomes worldwide. Results: Overall, outcomes for many tumour types 
continue to improve across Europe, including in regions with historically low 
survival such as Eastern Europe. Data on general cancer treatment reveal that 
the rate of innovative drug use in the UK has increased since 2009, just prior to 
the establishing of the Cancer Drugs Fund (CDF). Since the advent of the CDF, the 
UK has risen internationally from 11th place to 7th in terms of cancer survival 
rate; however, this improvement still leaves the UK as one of the lowest ranked 
European countries. Patients with colon cancer are ~20% less likely to receive 
biologics than those in other European countries; this may explain the results of 
other studies showing that survival rates in the UK continue to lag behind those 
in central Europe in the CDF/biologics era. ConClusions: Although survival rates 
continue to improve, there remain geographical disparities in some cancer types 
despite major advances in care pathways and treatment. The UK in particular 
continues to lag behind other countries. The CDF provides a vital service, giving 
patients access to innovative, life-extending treatments. The threat of losing this 
access route has serious implications for UK cancer treatment, which is already 
among the least successful in Europe.
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objeCtives: To provide an overview of drugs used by elderly in the year before 
colon cancer diagnosis and to compare this with a matched control group without 
cancer. Methods: Data were obtained from the population-based Netherlands 
Cancer Registry (NCR) and linked to the PHARMO Database Network, which 
includes complete longitudinal data obtained from out-patient pharmacies. All 
colon cancer patients aged ≥ 70 years diagnosed between 2000-2011 were included. 
Patients were matched 1:1 with controls on gender, year of birth and postal code. 
Differences in the proportion of users between cases and controls of each drug 
on WHO ATC-3 level were calculated using Chi2 tests. Drug use was defined in 
the year before colon cancer diagnosis or cohort entry date and during each quar-
ter of that year. Results: The study population consisted of 2,735 colon cancer 
patients and 2,735 matched cancer-free controls. 90% of cases and 69% of controls 
used ≥ 1 drug during the study period. The top 3 most frequently used drugs, 
based on the highest number of users among cases during the total year, were 
drugs for constipation (cases vs. controls 58% vs. 10%, p< 0.0001), antithrombotic 
agents (42% vs. 33%, p< 0.0001) and drugs for acid related disorders (35% vs. 22%, 
p< 0.0001). For all 3 drugs, the number of users in each quarter was higher among 
cases. Among cases, the number of users increased during the last quarter of 
the year for drugs for constipation (10% Q3 to 53% Q4) and drugs for acid related 
disorders (19% Q3 to 27% Q4). ConClusions: Our study demonstrates higher 
drug use among elderly colon cancer patients during the year before diagno-
sis as compared to a matched cancer-free control group, which increased even 
more during the last three months before colon cancer diagnosis. The effect of 
specific drugs on cancer treatment and outcome should be subject of further 
study.
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objeCtives: Eribulin mesylate is a microtubule inhibitor FDA approved in 2010 
for patients with MBC after treatment with at least two prior chemotherapeutic 
regimens. This study utilized real-world claims data to evaluate the utilization of 
eribulin mesylate by line of therapy at two and five years post launch to deter-
mine the degree to which patterns of utilization by line of therapy and payer type 
change over time without an associated change in labeling. Methods: Using data 
from the Cardinal Health Specialty Solutions Revenue Cycle Management medical 
claims database, patients who received 2 or more eribulin administrations and 
completed therapy between May 2014 and April 2015 were included in the current 
analyses (n= 368). The distribution of this study group was compared to a similar 
patient population identified as having completed therapy between April 2011 and 
all scoring of drugs varied considerably, with scores ranging from 1 to 13 and with 
just under half of drugs (7/15) receiving a score of 1 or no score at all. In contrast, 
the quality of evidence provided by manufacturers varied to a much lesser extent, 
with the majority of drugs receiving a score of “B” which, according to the scor-
ing system, indicates one good-quality published Phase III randomised controlled 
trial. ConClusions: Understanding the way the UK CDF makes decisions on the 
provision of breast cancer treatments can help pharmaceutical companies prepare 
evidence in order to maximise market access. Identifying strengths and weaknesses 
in the scoring of previous submissions to the CDF can also optimise submissions to 
give patients with breast cancer the best chance of access to innovative medicines.
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objeCtives: Approved by the Food and Drug Administration (FDA) in 2010, sipuleucel-
T was the first personalised “cancer vaccine” to treat prostate cancer in the meta-
static, non-symptomatic population of 30,000 men in the US. Sipuleucel-T is prepared 
individually for each patient and infused in three sessions over one-month. In 2015, 
sipuleucel-T’s owner, Dendreon, filed for bankruptcy. This search aimed to review how 
this innovative product failed to achieve commercial success. Methods: PubMed 
and internet search focused on pricing, reimbursement and market access. Results: 
Sipuleucel-T’s FDA approval was delayed by 3 years, reportedly because of the vac-
cine’s new mechanism of action. Sipuleucel-Twas cleared by the European Medicines 
Agency two years later, but other locations were not approached. It was priced at 
$93,000 for a course of treatment. The high price combined with the company’s late 
management of reimbursement of the vaccine by the US Centers for Medicare & 
Medicaid Services (CMS) resulted in another year of delay in accessing the market. In 
spite of positive recommendation by the National Comprehensive Cancer Network, 
sipuleucel-T’s complex administration, high price and uncertainty about the reim-
bursement status deterred doctors from the product. Further, the vaccine’s supply was 
limited during the first year of launch, due to small manufacturing capacity. Two oral 
metastatic prostate cancer drugs with similar survival benefit reached the US market 
one and two years after sipuleucel-T. Even though Dendreon’s market capitalization 
topped $7.5 billion following FDA’s approval sipuleucel-T, this value degraded gradu-
ally until the firm’s bankruptcy five years later. ConClusions: The bankruptcy of 
Dendreon was largely due to the delay in reaching FDA approval and CMS coverage 
and the high cost that had to be incurred by providers up-front. Licensing sipuleucel-
T to a Pharma company more experienced in the market access pathway may have 
saved the company and the product.
PCN276
a New PaCe for the smC?
Macaulay R
PAREXEL, London, UK
objeCtives: Access for oncology drugs can be severely constrained under obligate 
cost-utility HTA bodies, such as the SMC, NICE, pCODR and PBAC. Indeed the rejection 
rate for NICE oncology single technology appraisals is over three-times that of non-
oncology ones (40% vs. 13%). In April 2014, the SMC announced it would adopt a more 
flexible approach in its review of end-of-life and orphan therapies. Going forwards, 
if the initial SMC advice is not to recommend, a Patient and Clinician Engagement 
Group (PACE) meeting can be convened. This meeting aims to capture the benefits 
of the medicine outside of the considerations of the conventional process and was 
anticipated to constitute a “major factor” in the SMC decision. This research aims to 
evaluate what effect PACE groups have had on SMC appraisal outcomes. Methods: 
All SMC approvals from April 2014 were identified and the recommendation, indica-
tion and whether a PACE meeting was convened was extracted. Results: 87 SMC 
appraisals were identified, 46 were recommended, 26 were approved with restrictions 
and 15 were not recommended. 25 appraisals were for oncology drugs, 28% of which 
(7/25) were rejected compared to 13% (8/62) of non-oncologics. PACE meetings were 
convened in 20 appraisals 11 of which were recommended, 4 restricted and 5 rejected. 
19/20 were for oncology drugs, representing 76% (19/25) of all oncology apprais-
als. ConClusions: This new SMC PACE process is being well utilized, particularly 
in the appraisals of oncologics, and has resulted in many appraisals that would have 
been rejected being recommended instead. This has produced more timely market 
access for patients, without the need for multiple rounds of resubmissions, as was 
often the case pre-PACE. Nevertheless, rejection rates of oncology drugs still remain 
substantially higher than for non-oncology drugs.
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objeCtives: In Italy, federalism in health system leads to an increasingly frag-
mented and geographically differentiated Health, often even within the same region 
and also leads to a long and complex process for drugs market access and to get 
the access of patients. We conducted a survey in four regions in order to assess the 
inclusion of new cancer drugs within the regional formularies evaluating the time 
to access. Methods: Once a drug is reimbursed by the national assessment body 
(AIFA), a further step consists in obtaining the authorization for reimbursement 
by the regional health systems (RHS), many of which have their own formulary 
of reimbursed pharmaceutical drugs. Currently, 16 Italian regions have adopted 
a regional formulary. The selected Regions for this analysis are Emilia Romagna, 
Piemonte, Lazio and Sardegna. We considered six new oncology drugs reimbursed 
by AIFA in 2014, excluding three oncology drugs that bypass the regional evaluation 
process since they respond to the requirement of therapeutic innovation. Results: 
Nowadays, only the Regions of Piemonte and Emilia Romagna have evaluated all 
